Abstract

This Cancer Center Support Grant provides support for shared resources and services for the four interdisciplinary research programs of the Roger Williams Cancer Center: Drug Development, Cancer Biology, Radiation Biology, and Clinical Pharmacology and Clinical Oncology. The goals of the Center are to generate new scientific information relevant to the treatment of patients with cancer and, through research and education, to foster a higher level of cancer care in the region served by the Center. Significant emphasis on interaction among investigators in a variety of disciplines results in an efficient translation of basic scientific information into clinical studies, as well as important feedback from the clinic to the laboratory. The shared resources and services provided by this grant are all essential to the conduct of the Center's research. They consist of: Medicinal Chemistry, Tissue Culture, Instrumentation, Radiation Medicine, Animal Care, Clinical Trials Management and Biostatistics.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013943-19
Application #
3101363
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1979-08-01
Project End
1993-04-30
Budget Start
1991-05-01
Budget End
1992-04-30
Support Year
19
Fiscal Year
1991
Total Cost
Indirect Cost

  Institution

Name
Roger Williams Hospital
Department
Type
DUNS #
City
Providence
State
RI
Country
United States
Zip Code
02908

  Publications

Trunzo, Joseph J; Pinto, Bernardine M (2003) Social support as a mediator of optimism and distress in breast cancer survivors. J Consult Clin Psychol 71:805-11
Pinto, Bernardine M; Trunzo, Joseph J; Reiss, Philip et al. (2002) Exercise participation after diagnosis of breast cancer: trends and effects on mood and quality of life. Psychooncology 11:389-400
Wanebo, H J; Belliveau, J F (1999) A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion. Cancer Chemother Pharmacol 43:427-34
Oguey, D; Dumenco, L L; Pierce, R H et al. (1996) Analysis of the tumorigenicity of the X gene of hepatitis B virus in a nontransformed hepatocyte cell line and the effects of cotransfection with a murine p53 mutant equivalent to human codon 249. Hepatology 24:1024-33
Elenitoba-Johnson, K S; Medeiros, L J; Khorsand, J et al. (1996) P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease. Am J Clin Pathol 106:728-38
Davol, P; Frackelton Jr, A R (1996) The mitotoxin, basic fibroblast growth factor-saporin, effectively targets human prostatic carcinoma in an animal model. J Urol 156:1174-9
Wolf, D A; Wang, S; Panzica, M A et al. (1996) Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products. Cancer Res 56:5012-22
Davol, P; Beitz, J G; Mohler, M et al. (1995) Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Cancer 76:79-85
Davol, P; Beitz, J G; Frackelton Jr, A R (1995) Autocrine down-regulation of basic fibroblast growth factor receptors causes mitotoxin resistance in a human melanoma cell line. J Invest Dermatol 104:916-21
Rosmarin, A G; Caprio, D; Levy, R et al. (1995) CD18 (beta 2 leukocyte integrin) promoter requires PU.1 transcription factor for myeloid activity. Proc Natl Acad Sci U S A 92:801-5

Showing the most recent 10 out of 34 publications